清髓性与减低强度预处理下HLA单倍体与全相合无关供者移植联合PTCy预防的比较
该研究比较了2011至2018年间2036例HLA单倍体移植与284例全相合无关供者移植、均采用PTCy方案预防GVHD的成人急性白血病或MDS患者结局。减低强度预处理中,全相合无关供者的移植失败、急性GVHD、非复发死亡更低,无病生存与总生存更高;清髓性预处理中两组移植失败、复发、非复发死亡及生存无差异。
要点
- 减低强度预处理下,全相合无关供者移植的2年无病生存55% vs 单倍体41%,总生存67% vs 54%。
- 清髓性预处理下,全相合无关供者的血小板恢复更高,但移植失败、复发、生存与单倍体无差异。
- 全相合无关供者尤其应优先考虑用于减低强度预处理移植。
核心结论
- 在采用PTCy预防GVHD的成人急性白血病或MDS移植中,减低强度预处理下全相合无关供者移植结局优于单倍体移植。
- 清髓性预处理下,全相合无关供者与单倍体移植在移植失败、复发、非复发死亡及生存方面无差异。
- 数据支持供受者HLA匹配的重要性,全相合无关供者为优先供者,尤其对于减低强度预处理移植。
研究设计与样本
- 回顾性比较2011至2018年2036例HLA单倍体移植与284例全相合无关供者移植。
- 所有移植均采用PTCy/钙调神经磷酸酶抑制剂/霉酚酸酯GVHD预防。
- 采用Cox回归模型比较供者类型间结局,并分别分析清髓性与减低强度预处理方案。
主要发现
- 减低强度预处理中,全相合无关供者较单倍体的2年移植失败率3% vs 11%。
临床怎么用
- 对于拟行减低强度预处理移植的成人急性白血病或MDS患者,优先选择全相合无关供者而非单倍体供者。
- 对于清髓性预处理移植,单倍体与全相合无关供者均可考虑,因生存结局无差异。
局限性
- 研究为回顾性比较,可能存在选择偏倚。
- 全相合无关供者样本量284例,远小于单倍体2036例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Posttransplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis has enabled haploidentical (Haplo) transplantation to be performed with results similar to those after matched unrelated donor (MUD) transplantation with traditional prophylaxis. The relative value of transplantation with MUD vs Haplo donors when both groups receive PTCy/calcineurin inhibitor/mycophenolate GVHD prophylaxis is not known. We compared outcomes after 2036 Haplo and 284 MUD transplantations with PTCy GVHD prophylaxis for acute leukemia or myelodysplastic syndrome in adults from 2011 through 2018. Cox regression models were built to compare outcomes between donor types. Recipients of myeloablative and reduced-intensity regimens were analyzed separately. Among recipients of reduced-intensity regimens, 2-year graft failure (3% vs 11%), acute grades 2 to 4 GVHD (hazards ratio [HR], 0.70; P = .022), acute grades 3 and 4 GVHD (HR, 0.41; P = .016), and nonrelapse mortality (HR, 0.43; P = .0008) were lower after MUD than with Haplo donor transplantation. Consequently, disease-free (HR, 0.74; P = .008; 55% vs 41%) and overall (HR, 0.65; P = .001; 67% vs 54%) survival were higher with MUD than with Haplo transplants. Among recipients of myeloablative regimens, day-100 platelet recovery (95% vs 88%) was higher and grades 3 and 4 acute (HR, 0.39; P = .07) and chronic GVHD (HR, 0.66; P = .05) were lower after MUD than with Haplo donor transplantation. There were no differences in graft failure, relapse, nonrelapse mortality, and disease-free and overall survival between donor types with myeloablative conditioning regimens. These data extend and confirm the importance of donor-recipient HLA matching for allogeneic transplantation. A MUD is the preferred donor, especially for transplantations with reduced-intensity conditioning regimens.
引用
- Gooptu M, Romee R, St Martin A, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021. PMID: 34292325. doi:10.1182/blood.2021011281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。